Redhill Biopharma
RDHL
24 hedge funds and large institutions have $16.2M invested in Redhill Biopharma in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 24 → 24 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
20% less capital invested
Capital invested by funds: $20.1M → $16.2M (-$3.98M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$135K |
| 2 |
FM
Family Management
New York
|
+$86.5K |
| 3 |
Morgan Stanley
New York
|
+$48.1K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$38.5K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$28.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.04M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$423K |
| 3 |
Renaissance Technologies
New York
|
-$356K |
| 4 |
Jane Street
New York
|
-$276K |
| 5 |
VanEck Associates
New York
|
-$240K |
RDHL Hedge Fund Activity: Q2 2017 in Review
24 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2017, worth a combined $16.2M — down 20% from $20.1M a quarter earlier.
Fund positioning in RDHL was balanced in Q2 2017: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was DZ Bank, opening a new position worth an estimated $135K. The largest seller was Sabby Management, exiting entirely with an estimated $1.04M sold.
- 24 institutional investors held Redhill Biopharma (RDHL) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $16.2M of Redhill Biopharma stock for Q2 2017, down 20% quarter-over-quarter.
- 3 funds opened new Redhill Biopharma positions in Q2 2017 and 3 closed out, a net change of 0 holders.
- The largest Redhill Biopharma buyer in Q2 2017 was DZ Bank, an estimated $135K added.
- The largest Redhill Biopharma seller in Q2 2017 was Sabby Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2017.